Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

NCT03180840 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

BIOLOGICAL: Pegunigalsidase alfa

Sponsor

Protalix

Collaborators

[object Object]